Genenta Science S.p.A.(GNTA)Earnings, Financials & Key Ratios
GNTA•NASDAQ
$1.81
Price updated Jun 27, 2026
AboutGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.Show more
- Revenue$0
- EBITDA-$6M+37.8%
- Net Income-$6M+32.6%
- EPS (Diluted)-0.33+32.7%
- ROE-36.53%+35.4%
GNTA Price & Volume
Genenta Science S.p.A. (GNTA) stock price & volume — 10-year historical chart
Loading chart...
GNTA Growth Metrics
Genenta Science S.p.A. (GNTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM25.45%
Return on Capital
10 Years-34.7%
5 Years-37.64%
3 Years-45.16%
Last Year-29.85%
Peers Comparison
Key metrics vs top competitors for Genenta Science S.p.A. (GNTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.81 | $34.66M | -4.81 | — | — | -36.53% | — | |
| $0.04 | $16.57M | -0.09 | -31.57% | -356.89% | — | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $3.25 | $354.88M | -1.62 | — | — | -70.79% | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — |
Compare GNTA vs Peers
Genenta Science S.p.A. (GNTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GNTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GNTA Frequently Asked Questions
Genenta Science S.p.A. (GNTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GNTA profitable?
Genenta Science S.p.A. (GNTA) reported a net loss of $15.4M for fiscal year 2025.
Dividend & Returns
What is GNTA's return on equity?
Genenta Science S.p.A. (GNTA) has a return on equity (ROE) of -36.5%. Negative ROE indicates the company is unprofitable.
What is Genenta Science S.p.A.'s free cash flow?
Genenta Science S.p.A. (GNTA) had negative free cash flow of $14.0M in fiscal year 2025, likely due to heavy capital investments.